Sign inJoin free

Watch / Markets

Three quality stocks on Claude's radar

21 Sept 202612:01

Three quality stocks on Claude's radar

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points:

  • Walker sees HUB24 (ASX: HUB) as the most attractive of the three, with recurring revenue and a strong competitive position despite market and regulatory pressures.

  • TechnologyOne (ASX:TNE) remains a high-quality long-term holding, although Walker is cautious about its reliance on a strong second half to meet guidance.

  • Walker continues to favour Pro Medicus (ASX:PME) but says its valuation needs to fall to around $120–$130 before he would consider buying more.

A Rich Life's Claude Walker says quality stocks should combine strong management, predictable or growing demand and a competitive advantage that allows them to reinvest at attractive returns. He points to Pro Medicus, HUB24 and TechnologyOne as examples, with all three reporting recurring revenue, profitability, strong balance sheets and free cash flow.

Walker says HUB24 is the only one of the three where he has recently added, after previously selling above $80. He says the platform remains exposed to market movements through funds under administration and has been affected by regulatory concerns across the wealth-management sector. TechnologyOne also remains attractive, with sticky customers and recurring revenue, although Walker is watching whether a strong second half is needed to meet guidance.

Pro Medicus remains Walker’s preferred business but not at its current valuation. He estimates the stock becomes more attractive around $120–$130, while maintaining a positive long-term view of its competitive position in medical imaging. Walker says its technology, growing radiologist adoption and potential role as an ecosystem for AI-enabled radiology give it significant advantages, although growth is likely to moderate as the company gets larger.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy